Core Insights - The strategic partnership between LeXin Medical and Ping An Health aims to create a comprehensive health management model focusing on prevention, monitoring, and intervention [1][2] - LeXin Medical specializes in digital chronic disease management and has over 20 years of experience in developing medical-grade remote health monitoring devices [1] - Ping An Health, as a leading internet healthcare company, offers a unique business model based on managed healthcare, family doctor membership, and O2O health services [1] Company Collaboration - The collaboration will leverage the strengths of both companies to focus on conditions such as myocardial infarction and cerebral infarction, establishing a closed-loop digital management pathway [1] - LeXin Medical will provide remote dynamic electrocardiogram services and digital blood pressure management, integrating with Ping An Health's online consultation and health management resources [1] - This initiative aligns with the "Healthy China" strategy and promotes the advancement of medical services towards intelligence and inclusivity [1] Future Expansion - The partnership is seen as a starting point for building a new ecosystem in smart healthcare, with plans to expand into multiple core health management dimensions such as blood sugar, blood pressure, and weight [2] - The goal is to implement a comprehensive digital health service that manages multiple diseases and links various health indicators [2]

乐心医疗：公司申报的血糖仪医疗器械注册申请事宜已获受理 智通财经5月20日电，乐心医疗(300562.SZ)公告称，近日收到广东药监局的通知，公司申报的血糖仪医 疗器械注册申请事宜已获受理。该产品由便携式主机和软件组成，供糖尿病人家庭使用，通过体外定量 检测成人新鲜静脉全血样本和毛细血管全血样本中的葡萄糖浓度，监测血糖控制效果。血糖仪GBZ41-B 具备蓝牙功能，可将测量结果上传至指定APP。此次医疗器械注册的受理有助于公司拓展国内业务，增 强市场拓展能力，推动产品在远程慢病管理领域的应用场景落地。 ...

| 产品 名称 | 申请事项 | 受理号 | 分类 | 型号 | 结构及组成 | 适用范围 | | --- | --- | --- | --- | --- | --- | --- | | | 第二类医 | | | | 该产品主要由便 | 本产品仅供成人体外监测使用，供医疗 机构中专业人员专业检测以及糖尿病患 | | 血糖仪 | 疗器械注 | 00106001202 | II 类 | GBZ41-B、 | 携式主机、软件 | 者自我血糖监测。血糖仪不能用于糖尿 | | | | 50389 | | GBZ41 | （ 发 布 版 本 号 | | | | 册证核发 | | | | A.01）组成。 | 病诊断，可用于辅助监测患者血糖控制 | | | | | | | | 的有效性，结果以血浆血糖值为参考。 | 广东乐心医疗电子股份有限公司 关于申报医疗器械注册证获得受理的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 广东乐心医疗电子股份有限公司（以下简称"公司"）近日收到广东省药品 监督管理局（以下简称"广东药监局"）的通知，获悉公司申报的血糖仪医疗器 械注册 ...

关于变更持续督导保荐代表人的公告 乐心医疗 2025 年公告 证券代码：300562 证券简称：乐心医疗 公告编号：2025-043 广东乐心医疗电子股份有限公司 公司董事会对朱宏先生在担任公司保荐代表人期间所做出的贡献表示衷心 的感谢！ 特此公告。 广东乐心医疗电子股份有限公司 2025 年 05 月 16 日 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 广东乐心医疗电子股份有限公司（以下简称"公司"）于近日收到保荐机构 国泰海通证券股份有限公司（以下简称"国泰海通"）出具的《国泰海通证券股 份有限公司关于更换广东乐心医疗电子股份有限公司持续督导保荐代表人的函》。 国泰海通为公司向特定对象发行股票的保荐机构，指定桑继春女士、朱宏先生为 公司向特定对象发行股票项目持续督导保荐代表人，负责持续督导工作。由于原 保荐代表人朱宏先生因个人原因离职，无法继续从事对公司的持续督导工作。为 保证持续督导工作的有序进行，国泰海通现委派保荐代表人吴超智先生（简历见 附件）接替朱宏先生继续履行持续督导工作。本次保荐代表人更换后，公司向特 定对象发行股票项目持续督导保荐代表人 ...

北京世辉（深圳）律师事务所 关于广东乐心医疗电子股份有限公司 2025 年第一次临时股东大会的 法律意见书 致：广东乐心医疗电子股份有限公司 北京世辉（深圳）律师事务所（以下简称"世辉"或"本所"）接受广东乐 心医疗电子股份有限公司（以下简称"公司"）的委托，根据《中华人民共和国 证券法》（以下简称"《证券法》"）、《中华人民共和国公司法》（以下简称 "《公司法》"）、中国证券监督管理委员会《上市公司股东大会规则》（以下 简称"《股东大会规则》"）等法律、行政法规、规范性文件和现行有效的《广 东乐心医疗电子股份有限公司章程》（以下简称"《公司章程》"）的规定，指 派律师出席了公司于 2025 年 5 月 13 日召开的 2025 年第一次临时股东大会（以 下简称"本次股东大会"），并就本次股东大会的相关事项出具本法律意见书。 为出具本法律意见书，本所律师审查了公司提供的以下文件，包括但不限于： 1．《公司章程》； 2．《第四届董事会第二十三次会议决议公告》； 3．《关于召开 2025 年第一次临时股东大会的通知》； 4．公司本次股东大会股权登记日的股东名册； 5．公司本次股东大会股东到会登记记录及凭证资料； ...

乐心医疗 2025 年公告 证券代码：300562 证券简称：乐心医疗 公告编号：2025-042 广东乐心医疗电子股份有限公司 特别提示： 1、本次股东大会无否决议案的情形。 1、会议召集人：公司董事会 2025年第一次临时股东大会决议公告 2、会议主持人：董事长潘伟潮先生 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、会议召开和出席情况 （一）会议召开情况 2、本次股东大会不涉及变更以往股东大会已通过的决议。 3、本次股东大会采取现场投票和网络投票相结合的表决方式。 3、会议召开时间： 现场会议时间：2025年05月13日（星期二）下午15:00-16:00 其中：通过深圳证券交易所交易系统进行网络投票的具体时间为2025年05 月13日上午09:15-09:25，09:30-11:30，下午13:00-15:00；通过深圳证券交易所互 联网投票系统投票的具体时间为2025年05月13日09:15至2025年05月13日15:00。 4、会议召开方式： 本次股东大会采取现场投票与网络投票相结合的方式召开： （1）现场投票：股东本人出席现场会议或者通过 ...

Group 1 - The core viewpoint of the news highlights the performance and valuation of Leksin Medical, indicating a recent stock price increase and a low rolling PE ratio compared to the industry average [1][2]. - As of May 12, Leksin Medical's stock closed at 14.85 yuan, up 2.70%, with a rolling PE ratio of 45.72, marking a new low in 24 days and a total market capitalization of 3.229 billion yuan [1]. - The average PE ratio for the medical device industry is 49.84, with a median of 36.59, positioning Leksin Medical at the 87th rank within the industry [1][3]. Group 2 - Leksin Medical specializes in health IoT and digital health services, offering products such as smart electronic blood pressure monitors, health scales, and ECG monitoring devices [2]. - The company is recognized as a national high-tech enterprise and has established several engineering technology research centers, focusing on the R&D, production, and sales of home medical health electronic products [2]. - In the latest quarterly report for Q1 2025, Leksin Medical reported revenue of 273 million yuan, a year-on-year increase of 9.90%, and a net profit of 22.942 million yuan, reflecting a significant year-on-year growth of 67.88% with a gross profit margin of 37.38% [2].

Group 1 - The core business of the company is health IoT and digital health services, with main products including smart electronic blood pressure monitors, electronic health scales, smart blood glucose monitoring products, fat measuring devices, ECG monitoring equipment, smart bands, and smartwatches [2] - The company has achieved ISO certifications for medical device quality management and has received international certifications such as FDA registration, EU CE certification, and GMP certification from South Korea, indicating its products meet advanced international quality standards [2] - In the latest quarterly report for Q1 2025, the company reported revenue of 273 million yuan, a year-on-year increase of 9.90%, and a net profit of 22.94 million yuan, a year-on-year increase of 67.88%, with a gross profit margin of 37.38% [2] Group 2 - As of May 9, the company's stock closed at 14.46 yuan, down 2.10%, with a rolling PE ratio of 44.51 times and a total market capitalization of 3.145 billion yuan [1] - The average PE ratio for the medical device industry is 48.98 times, with a median of 36.16 times, placing the company at the 86th position in the industry ranking [1][3] - On May 9, the company experienced a net outflow of 9.9992 million yuan in main funds, with a total outflow of 32.6116 million yuan over the past five days [1]

Group 1 - The core business of the company is health IoT and digital health services, with main products including smart electronic blood pressure monitors, electronic health scales, smart blood glucose monitoring products, fat measuring devices, ECG monitoring equipment, smart bands, and smart watches [2] - The company is recognized as a national high-tech enterprise and has established several research and development centers, focusing on the R&D, production, and sales of home medical health electronic products [2] - The latest financial report indicates that for Q1 2025, the company achieved a revenue of 273 million yuan, representing a year-on-year increase of 9.90%, and a net profit of 22.94 million yuan, reflecting a year-on-year growth of 67.88% with a gross profit margin of 37.38% [2] Group 2 - As of April 29, the company's stock closed at 14.21 yuan, up 3.50%, with a rolling PE ratio of 43.75, marking a new low in 18 days, and a total market capitalization of 3.09 billion yuan [1] - In terms of industry comparison, the average PE ratio for the medical device industry is 47.74, with a median of 36.15, placing the company at the 84th position in the industry ranking [1][3] - On April 29, the company experienced a net outflow of 2.93 million yuan in principal funds, although the overall trend over the past five days showed a net inflow of 32.09 million yuan [1]

Investment Rating - The report does not explicitly state an investment rating for the industry, but it suggests a long-term focus on domestic innovative drugs in the oncology field and AI medical investment opportunities [3][4]. Core Insights - The pharmaceutical and biotechnology sector saw a weekly increase of 1.16%, outperforming the Wind All A index (1.15%) and the CSI 300 index (0.38%) [3][8]. - The upcoming ASCO conference is highlighted as a significant event for domestic innovative drug companies, with over 70 oral presentations and more than 10 major studies expected [3][4]. - The Ministry of Industry and Information Technology and six other departments issued a plan for the digital transformation of the pharmaceutical industry, aiming for significant advancements by 2027 and full coverage by 2030 [3][4]. Market Weekly Review - The pharmaceutical and biotechnology sector increased by 1.16% from April 21 to April 25, outperforming the Wind All A index and the CSI 300 index [3][8]. - Notable performers included medical research outsourcing (6.34%) and raw materials (4.72%), while blood products (-3.26%) and vaccines (-6.38%) continued to decline [3][9]. - Individual stock performances showed significant gains for Yong'an Pharmaceutical (31.4%), Shuyou Shen (28.4%), and Erkang Pharmaceutical (27.7%), while *ST Jiyuan (-43.2%), Nanhua Biological (-35.3%), and Shuangcheng Pharmaceutical (-27.7%) faced substantial losses [3][11]. Industry News and Key Company Announcements - On April 25, Kangfang Bio announced FDA approval for its drug Anike for the treatment of recurrent or metastatic nasopharyngeal carcinoma [12]. - The same day, Kangfang Bio also reported the approval of its PD-1/VEGF bispecific antibody for first-line treatment of specific lung cancer types [13]. - The digital transformation plan for the pharmaceutical industry aims to enhance competitiveness and quality management through AI and data integration by 2030 [3][4].